

6-2008-2098 | a Novel pre-treatment for the Prevention of Allergic reactions to medicines using a drug-free Carriers

[Barenholz Yechezkel](#), HUJI, School of Medicine - IMRIC, Biochemistry and Molecular Biology

Background

- Intravenous injection of some liposomal drugs, diagnostic agents, micelles and other lipid-based nanoparticles cause hypersensitivity reactions in up to 45% of patients, which appear to be initiated by the complement system (C) of the immune system.
- Liposomes, Micelles, and other particulate drug carriers which do not carry C inhibitors on their surfaces will activate these hypersensitive reactions.

Our Innovation

a Novel treatment to prevent Allergic reactions to medicines by using a placebo drug-free Carrier, prior to the administration of particulate medicines

Applications for use:

Preventing an allergic reactions to medicines

Key Features

- Technology specifically inhibits PCM-triggered C3a/C5a receptor-mediated complement activation-related pseudoallergy (CARPA) reactions
- Toxicology tests for this technology are very simple

The Opportunity

Opportunity to incorporate new technology with minimal regulatory process

Researcher Information biochemistry.huji.ac.il/faculty_barenholz.asp,
research.ekmd.huji.ac.il/researchers.asp?id=166, nanoscience.huji.ac.il/researchers/barenholz.htm

Patent Status

Granted US [9,078,812](#); Europe [2231190](#)

Contact for more information:



Keren-Or Amar
VP, Business Development, Healthcare

Yissum Research Development Company of the Hebrew University of Jerusalem

Hi-Tech Park, Edmond J. Safra Campus, Givat-Ram, Jerusalem
P.O. Box 39135, Jerusalem 91390 Israel
Telephone: 972-2-658-6688, Fax: 972-2-658-6689